

The Right Door for Hope, Recovery and Wellness

Chapter Title	Chapter #		Subject #
Recipient Rights	RR		137
Subject Title Clozaril (clozapine)	Adopted 2/26/96	Last Revised 4/2/22	Last Reviewed 12/27/04; 12/27/06; 3/27/08; 7/12/10; 6/27/11; 5/29/12; 9/23/13; 12/10/14; 9/23/15; 12/14/16; 12/20/17; 12/19/18; 12/18/19; 4/26/21; 5/24/21; 4/26/22; 4/24/23; 4/22/24

POLICY

Application

This policy shall apply to The Right Door for Hope, Recovery and Wellness and all services operated by or under contract with it.

1. Clozaril (clozapine)

1.1. It is the policy of The Right Door for Hope, Recovery and Wellness Authority that Clozaril will be prescribed and monitored in strict compliance with the Risk Evaluation and Mitigation Strategy (REMS) and Food and Drug Administration (FDA) standards. Medication will not be dispensed without a favorable report of the blood analysis. Blood will be drawn for white blood cell (WBC) laboratory analysis and reporting as follows:

1.1.1. weekly: for the first six months;

1.1.2. bi-weekly: for the period of six months to one year;

1.1.3. monthly: after one year.

1.2. If a person served misses more than two days of their medication, a prescriber would assess if the person served needs to titrate the medication again, but the lab would continue per REMS.

1.3. If treatment is discontinued for less than 30 days, continue monitoring as before. If treatment is discontinued for 30 days or more, monitor as if a new patient.

References

Food and Drug Administration (FDA) Standards

The Right Door for Hope, Recovery and Wellness

Chapter Title Recipient Rights	Chapter # RR		Subject # 137
Subject Title Clozaril (clozapine)	Adopted 2/26/96	Last Revised 4/2/22	Last Reviewed 12/27/04; 12/27/06; 3/27/08; 7/12/10; 6/27/11; 5/29/12; 9/23/13; 12/10/14; 9/23/15; 12/14/16; 12/20/17; 12/19/18; 12/18/19; 4/26/21; 5/24/21; 4/26/22; 4/24/23; 4/22/24

CARF Standards, Section "Pharmacotherapy"

Nancy Patera, Board Chairperson	Date		